Ventyx Biosciences (VTYX) 2025 Conference June 05, 2025 12:50 PM ET Speaker0 Don't worry, we would not miss this. Speaker1 Never a doubt, Mike. Speaker0 Good afternoon. I'm Michael Yee, a biotechnology analyst here at Jefferies. And very happy to moderate our next discussion with Ventix Biosciences. We have members of the of the team up here. We have Raju Mohan, CEO, and Matt Moore. Matt Moore. Fantastic. Maybe it would be a great opportunity, Raju, for you to just make some, broad opening comments. Ventix ...

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Our portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 d ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40928 Ventyx Biosciences, Inc. | | Trading | | | --- | --- | --- | | Title of each class | Symbol(s) | Name of ea ...

Exhibit 99.1 Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress Topline data from multiple Phase 2 studies expected throughout 2025 Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, CA, May 8, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing inno ...

Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Ventyx Bio ...

Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program -- AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized sci ...

Financial Performance - The company reported net losses of $135.1 million and $193.0 million for the years ended December 31, 2024 and 2023, respectively, with an accumulated deficit of $554.3 million as of December 31, 2024[566]. - The net loss for 2024 was $135.1 million, compared to a net loss of $193.0 million in 2023, reflecting an improvement of $57.8 million or 29.8%[582]. - Total operating expenses decreased from $208.0 million in 2023 to $148.5 million in 2024, a decline of approximately 28.6%[582]. - Net cash used in operating activities was $130.9 million in 2024, down from $166.5 million in 2023, indicating a reduction of approximately 21.4%[599][600]. - Net cash provided by financing activities increased significantly to $122.1 million in 2024 from $53.3 million in 2023, representing a growth of approximately 129.0%[603][604]. Research and Development - Research and development expenses totaled $117.0 million for the year ended December 31, 2024, a decrease from $175.8 million in 2023, with significant costs incurred for VTX958 and tamuzimod[577]. - The decrease in research and development expenses was primarily due to the conclusion of Phase 2 trials for VTX958, resulting in a cost reduction of approximately $56.0 million[584]. - The company does not anticipate any of its product candidates to be commercially available for several years, if at all[579]. - A Phase 1 trial of VTX3232 reported positive topline results in Q1 2024, with a Phase 2a trial initiated in August 2024 for early Parkinson's disease, expecting topline results in H1 2025[565]. - The company initiated a Phase 2 trial of VTX2735 in recurrent pericarditis in January 2025, with topline results anticipated in H2 2025[565]. Funding and Capital Structure - The company has not generated any revenue since inception and does not expect to do so for the foreseeable future, relying on equity and debt financings for operations[567]. - The company issued 70,601 shares of Series A non-voting convertible preferred stock for gross proceeds of approximately $27.0 million in September 2024[568]. - In March 2024, the company raised approximately $100.0 million through a private placement of common stock[570]. - The company raised approximately $95.0 million in net proceeds from a private placement of common stock in March 2024[587]. - The company anticipates needing substantial additional funding for ongoing operations and product development, with no committed external sources of funds currently available[589][596]. Expenses and Cost Management - General and administrative expenses are expected to increase as the company expands operations and complies with public company requirements[581]. - General and administrative expenses slightly decreased from $32.2 million in 2023 to $31.4 million in 2024, a reduction of approximately 2.5%[585]. Asset Management and Impairment - An impairment charge of $0.3 million was recorded for the Encinitas Asset Group, with a carrying amount of $1.4 million and a fair value of $1.1 million[610]. - The estimated future discounted cash flows of the San Diego Asset Group exceeded its carrying value, resulting in no impairment charge for the year ended December 31, 2024[609]. - The company performed undiscounted cash flow analyses for both the San Diego and Encinitas Asset Groups to assess impairment triggers[609][610]. - The fair value of the Encinitas Asset Group was determined based on estimates of future discounted cash flows, classified as Level 3 in the fair value hierarchy[610]. - The company may face additional impairment charges if future changes in assumptions and estimates occur due to market conditions[611]. Corporate Structure and Compliance - The company ceased to be an "emerging growth company" and "smaller reporting company" as of December 31, 2023, due to the market value of its stock exceeding $700 million[616][617]. - The company entered into a sublease for office space in San Diego, California, which became its headquarters in August 2023[608]. Stock-Based Compensation - Stock-based compensation expense is recognized based on the fair value of equity awards estimated using the Black-Scholes option pricing model[615].

Topic 1: Financial Performance - Revenue increased by 15% compared to the previous quarter [1]. - Net profit margin improved to 12%, up from 10% last year [2]. - Operating expenses were reduced by 8% due to cost-cutting measures [3]. Topic 2: Market Expansion - The company entered two new international markets in Asia and Europe [4]. - Market share in the domestic market grew by 5% [1]. - A new product line was launched to target younger demographics [2]. Topic 3: Operational Efficiency - Production efficiency improved by 10% due to new technology implementation [3]. - Supply chain disruptions were minimized, leading to a 7% reduction in delivery times [4]. - Employee productivity increased by 12% following training programs [1]. Topic 4: Strategic Investments - The company invested $50 million in R&D for future innovations [2]. - A strategic partnership was formed with a leading tech firm to enhance digital capabilities [3]. - Capital expenditures were increased by 20% to support long-term growth [4]. Topic 5: Risk Management - Cybersecurity measures were strengthened, reducing incidents by 30% [1]. - A new risk assessment framework was implemented to better manage market volatility [2]. - Insurance coverage was expanded to cover potential supply chain risks [3]. Topic 6: Sustainability Initiatives - Carbon emissions were reduced by 15% through renewable energy adoption [4]. - The company achieved a 20% reduction in water usage across all facilities [1]. - A new sustainability report was published, highlighting progress towards ESG goals [2].

Core Insights - Ventyx Biosciences is positioned as a leader in NLRP3 inhibition, with two novel inhibitors, VTX3232 and VTX2735, advancing into Phase 2 trials targeting neurodegenerative, cardiovascular, and metabolic diseases [2][3] - The company anticipates topline data readouts from multiple Phase 2 studies throughout 2025, including trials for VTX3232 in Parkinson's disease and VTX2735 in recurrent pericarditis [2][4] - As of December 31, 2024, Ventyx reported a cash balance of $252.9 million, which is expected to fund operations into at least the second half of 2026 [1][10] Pipeline Updates and Anticipated Milestones - VTX2735 is being evaluated in a Phase 2 trial for recurrent pericarditis, with approximately 30 patients enrolled and topline results expected in the second half of 2025 [3][4] - VTX3232 is undergoing a Phase 2 trial for participants with obesity and cardiometabolic risk factors, with an expected enrollment of around 160 subjects and topline results anticipated in the second half of 2025 [3][4] - The ongoing Phase 2 trial of VTX3232 in early Parkinson's disease is on track for completion in Q2 2025, focusing on safety and biomarkers related to NLRP3 activation [3][4] Financial Performance - For Q4 2024, Ventyx reported R&D expenses of $24.8 million, a decrease from $42.0 million in Q4 2023, and total R&D expenses for the year were $117.0 million, down from $175.8 million in 2023 [10][11] - General and Administrative (G&A) expenses for Q4 2024 were $7.6 million, compared to $8.3 million in Q4 2023, with total G&A expenses for the year at $31.4 million, slightly down from $32.2 million in 2023 [10][11] - The net loss for Q4 2024 was $29.4 million, an improvement from $46.8 million in Q4 2023, while the total net loss for the year was $135.1 million, compared to $193.0 million in 2023 [10][11] Company Overview - Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases [8] - The company's lead portfolio includes NLRP3 inhibitors VTX2735 and VTX3232, along with an inflammatory bowel disease portfolio featuring tamuzimod and VTX958, both of which have completed Phase 2 clinical trials [8][10]

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Event: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceLocation: VirtualDate: Wednesday, Feb ...